THERAPEUTIC EFFECTS OF ALPHA-LIPOIC ACID IN POSTMENOPAUSAL PATIENTS WITH TYPE 2 DIABETES AND OSTEOARTHRITIS AND ITS EFFECT ON HYPERVISFATINEMIA
DOI:
https://doi.org/10.21856/j-PEP.2024.1.03Keywords:
alpha-lipoic acid, osteoarthritis, type 2 diabetes, visfatin, postmenopause, comorbid combinationAbstract
α-Lipoic acid is widely used in many areas of treatment. Along with other means, it is an important part of the global fight against diabetes, which is currently quite widely publicized, while its effect on adipocytokine status, including on the level of visfatin, and on the clinical manifestations of osteoarthritis in women, especially during menopause, needs further study. Purpose: To assess the effect of the proposed therapy regimen using α-lipoic acid on metabolic parameters, visfatin level, and also on the clinical manifestations of osteoarthritis in postmenopausal patients with type 2 diabetes and osteoarthritis.
Materials and methods. For the study, 44 age-matched women with type 2 diabetes and osteoarthritis were selected, who were divided into 2 groups: patients who additionally took α-lipoic acid and those who did not take it. The daily dose of α-lipoic acid was 600 mg for 3 months. Determination of the level of visfatin in the blood serum of patients was carried out by the immunoenzymatic method on the "Labline-90" analyzer (Austria). An assessment of lipid and carbohydrate metabolism indicators and clinical manifestations of osteoarthritis (VAS – visual analog scale, and WOMAC – Western Ontario and McMaster Universities osteoarthritis Index) was carried out.
Results. It was found that patients who received α-lipoic acid had significantly lower VAS, WOMAC questionnaire scores after treatment than in the control group (p<0.05). A significant improvement in the general parameters of glucose-insulin metabolism was observed, but the most likely changes were noted in women taking α-lipoic acid. Thus, significantly lower blood insulin levels were found both compared to the value before treatment (respectively 21.5±4.4 and 31.3±3.1 μIU/mL, p<0.05) and compared to the data of the control group after treatment (29.4±1.2 μIU/mL, p=0.03). In women of group 1, a statistically significant decrease in the level of visfatin was noted after 12 weeks of complex therapy with the addition of α-lipoic acid (from 5.5 ± 1.0 ng/mL to 5.06 ± 1.0 ng/mL (p<0.001)).
Conclusions. A positive effect of a 12-week course of taking alpha-lipoic acid on the parameters of glucose-insulin metabolism, lipid metabolism, visfatin levels and clinical indicators of osteoarthritis in postmenopausal women with type 2 diabetes and osteoarthritis was revealed. The expediency of using alpha-lipoic acid as an additional component of the complex therapy of postmenopausal women with type 2 diabetes and osteoarthritis is substantiated.
References
Benca TM. Ukr Terapevt Zhurn 2019;1: 87-90. http://doi.org/10.30978/UTJ2019-1-87
Hevko UP, Dikova IG, Maksiv KhYa, et al. Vіsn Med Bіol Doslіdz 2020;4(6): 132-136. http://doi.org/10.11603/bmbr.2706-6290.2020.4.11827
Grishhenko OV, Grishhuk KA, Storchak AV, Vasil'eva IA. Zbіrnik naukovih prac' asocіacії akusherіv-gіnekologіv Ukraїni 2015;2(36): 41-46.
Kovalenko VM, Bortkevich OP. Ukr Revmatol Zhurn 2019;3(77): 33-44.
Zhuravleva LV, Lopіna N. Praktikujuchij Lіkar 2019;(1): 31-40.
Dworacκa M, Chuκanova G, Isκaκova S, et al. Eur J Pharm Sci 2018;117: 41-47. http://doi.org/10.1016/j.ejps.2018.02.009.
Ahmad VN, Mohd A, Ruslan NB, et al. J Translat Engineering Health Med 2020;23(2): 42-48. https://doi.org/10.22452/jummec.vol23no2.7
Smaliukh O, Svitlyk H, Zaremba O, Zaremba-Fedchyshyn O. Praktikujuchij Lіkar 2022;(2-3): 35-39.
Boccardi V, Taghizadeh M, Salek M, Sadegh J. Arterial Hypertension 2021;25(1): 29-38. http://doi.org/10.5603/AH.a2021.0001.
Aslfalah H, Jamilian M, Ansarihadipour H, et al. Int J Reprod Bio Med 2020;18: 1029-1038. http://doi.org//10.18502/ijrm.v18i12.80 24
Dupont J, Pollet-Villard X, Reverchon M. Horm Mol Biol Clin Invest 2015;24: 11-24. http://doi.org/10.1515/hmbci-2015-0034.
Mingbo Lv, Wenbo Z, Jize Q. Int J Clin Experim Med 2019;12(1): 1234-1241.
Askari A, Naghizadeh MM, Homayounfar R, et al. PLoS One 2016;11: e0164757.
Cherpіta VO. Ukr Terapevt Zhurn 2021;4: 45-50. https://doi.org/10.30978/UTJ2021-4-29
Azamar-Llamas D, Hernández-Molina G, Ramos-Ávalos B, et al. Mediators of Inflammation 2017; 5468023: 1-26. http://doi.org/10.1155/2017/5468023.
Dakroub A, Nasser S, Younis N, et al. Cells 2020;9(11): 2444. https://doi.org/10.3390/cells9112444
Diot M, Reverchon M, Ramé C, et al. Reproduction 2017;150(1): 53-63. https://doi.org/10.1530/REP-15-0021.
Bawah AT, et al. Lipids Health Dis 2019;18: 221. https://doi.org/10.1186/s12944-019-1169-2
Bitto A, et al. Endocrine 2017;55: 899-906. https://doi.org/10.1007/s12020-016-0968-8
Cukrovij dіabet u molodih ljudej ta doroslih: Unіfіkovanij klіnіchnij protokol pervinnoї, ekstrenoї, vtorinnoї (specіalіzovanoї) ta tretinnoї (visokospecіalіzovanoї) medichnoї dopomogi 2014, available at: http://mtd decgovua/images/dodatki/2014_1021_CD1_dor/2014_1021_ nakaz_CD1_ dor pdf.
Pervinnoї, vtorinnoї (specіalіzovanoї), tretinnoї (visokospecіalіzovanoї) medichnoї dopomogi ta medichnoї reabіlіtacії po osteoartrozu: Unіfіkovanij klіnіchnij protokol 2016, available at: http://www.dec.gov.ua/mtd/reestr.html.
Menopauzal'nі porushennja ta іnshі rozladi v perimenopauzal'nomu perіodі: Unіfіkovanij klіnіchnij protokol pervinnoї, ekstrenoї, vtorinnoї (specіalіzovanoї) ta tretinnoї (visokospecіalіzovanoї) medichnoї dopomogi 2022, available at: https://www.dec.gov.ua/wp-content/uploads/2022/06/37474-dn_1039_17_06_2022_dod.pdf.
Akbari M, Ostadmohammadi V, Tabrizi R, et al. Nutr Metab 2018;15: 39. https://doi.org/10.1186/s12986-018-0274-y
Christianty FM, Suharjono, Susilo I, Khotib J. Pharm Sci Res 2019;6(2): 124-130. https://doi.org/10.7454/psr.v6i2.4321
Buyukaydin B, Guler EM, Karaaslan T, et al. World J Diab 2020;11(7): 309-321. https://doi.org/10.4239/wjd.v11.i7.309
Madjidova Y, Usmanova D. Int Neurol J 2021;1(103): 38-41. https://doi.org /10.22141/2224-0713.1.103.2019.158637
Guo J, Gao S, Liu Z, et al. Lipids 2016;51: 1145-1152. https://doi.org 10.1007/s11745-016-4185-2.
Monastra G, De Grazia S, Cilaker Micili S, et al. Expert Opin Drug Deliv 2016;13: 1695-1708. https://doi.org/10.1080/17425247.2016.1200556.
Cheleschi S, et al. Cells 2019;8(8): 874. https://doi.org/10.3390/cells8080874
Wang J, Sun H, Fu Z, Liu M. Free Radic Res 2016;50: 767-780 https://doi.org/10.1080/10715762.2016.1174775.
Sun T, Gao F, Lin X, et al. Toxicol In Vitro 2014;28: 1242-1248 https://doi.org/10.1016/j.tiv.2014.06.003.
Bruyère O, Honvo G, Veronese N, et al. Semin Arthritis Rheum 2019;19: 30043-30045. https://doi.org/10.1016/j.semarthrit.2019.04.008.
Kaczor T. Nat Med J 2020;12(5): https://www.naturalmedicinejournal.com/journal/2020-05/highlighting-alpha-lipoic-acid-diabetes.
ISSN 
ISSN 
